TICKERNOMICS Sign up
Last Update: 2024-12-27 15:23:10
ADMA BIOLOGICS INC. ( ADMA ) https://www.admabiologics.com
17.89USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ADMA
295.80%
SPY
32.66%
ADMA
1390.83%
SPY
108.59%
ADMA
352.91%
SPY
302.52%
ADMA
62.64%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4379.54
4302.90
1.62
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
64.28
11.44
18.89
1.68
0.00
29.09
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
33.08
49.78
34.50
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.1904
45.55
47.67
0.78
Other Earnings and Cash Flow Stats:
ADMA BIOLOGICS INC. ( ADMA ) Net Income TTM ($MM) is 68.13
ADMA BIOLOGICS INC. ( ADMA ) Operating Income TTM ($MM) is 114.89
ADMA BIOLOGICS INC. ( ADMA ) Owners' Earnings Annual ($MM) is 0.00
ADMA BIOLOGICS INC. ( ADMA ) Current Price to Owners' Earnings ratio is 0.00
ADMA BIOLOGICS INC. ( ADMA ) EBITDA TTM ($MM) is 122.49
ADMA BIOLOGICS INC. ( ADMA ) EBITDA Margin is 34.50%
Capital Allocation:
ADMA BIOLOGICS INC. ( ADMA ) has paid 0.00 dividends per share and bought back -11.042803 million shares in the past 12 months
ADMA BIOLOGICS INC. ( ADMA ) has reduced its debt by 143.898412 million USD in the last 12 months
Capital Structure:
ADMA BIOLOGICS INC. ( ADMA ) Interest-bearing Debt ($MM) as of last quarter is 10
ADMA BIOLOGICS INC. ( ADMA ) Annual Working Capital Investments ($MM) are -12
ADMA BIOLOGICS INC. ( ADMA ) Book Value ($MM) as of last quarter is 231
ADMA BIOLOGICS INC. ( ADMA ) Debt/Capital as of last quarter is 4%
Other Balance Sheet Stats:
ADMA BIOLOGICS INC. ( ADMA ) has 86 million in cash on hand as of last quarter
ADMA BIOLOGICS INC. ( ADMA ) has 44 million of liabilities due within 12 months, and long term debt 131 as of last quarter
ADMA BIOLOGICS INC. ( ADMA ) has 244 common shares outstanding as of last quarter
ADMA BIOLOGICS INC. ( ADMA ) has 0 million USD of preferred stock value
Academic Scores:
ADMA BIOLOGICS INC. ( ADMA ) Altman Z-Score is 18.17 as of last quarter
ADMA BIOLOGICS INC. ( ADMA ) Piotroski Score is 7.00 as of last quarter
Corporate Governance:
ADMA BIOLOGICS INC. ( ADMA ) largest shareholder is owning shares at 0.00 ($MM) value
Tade Brad L.(an insider) Sold 15000 shares of ADMA BIOLOGICS INC. ( ADMA ) for the amount of $317250.00 on 2024-11-22
2.55% of ADMA BIOLOGICS INC. ( ADMA ) is held by insiders, and 84.38% is held by institutions
ADMA BIOLOGICS INC. ( ADMA ) went public on 2013-10-17
Other ADMA BIOLOGICS INC. ( ADMA ) financial metrics:
FCF:79.19
Unlevered Free Cash Flow:0.00
EPS:0.59
Operating Margin:33.08
Gross Profit Margin:49.78
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:61.94
Beta:0.78
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ADMA BIOLOGICS INC. ( ADMA ) :
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.